Russell Investments Group Ltd. Raises Stake in AtriCure, Inc. (NASDAQ:ATRC)

Russell Investments Group Ltd. boosted its position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 8.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 156,649 shares of the medical device company's stock after buying an additional 12,212 shares during the period. Russell Investments Group Ltd. owned approximately 0.32% of AtriCure worth $4,787,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Captrust Financial Advisors acquired a new position in shares of AtriCure in the 3rd quarter valued at about $230,000. State Street Corp increased its holdings in AtriCure by 4.9% in the third quarter. State Street Corp now owns 1,344,856 shares of the medical device company's stock worth $37,710,000 after purchasing an additional 63,002 shares in the last quarter. Geode Capital Management LLC lifted its stake in AtriCure by 2.9% in the third quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company's stock valued at $32,326,000 after buying an additional 32,676 shares during the period. Franklin Resources Inc. boosted its holdings in shares of AtriCure by 0.9% during the 3rd quarter. Franklin Resources Inc. now owns 56,843 shares of the medical device company's stock worth $1,569,000 after buying an additional 484 shares in the last quarter. Finally, Blue Trust Inc. grew its position in shares of AtriCure by 1.8% during the 4th quarter. Blue Trust Inc. now owns 14,751 shares of the medical device company's stock worth $414,000 after buying an additional 265 shares during the period. Institutional investors own 99.11% of the company's stock.

Insider Activity

In related news, Director Karen Prange sold 6,100 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the transaction, the director now directly owns 17,828 shares in the company, valued at approximately $679,603.36. The trade was a 25.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Stifel Nicolaus boosted their target price on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Piper Sandler increased their price objective on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Needham & Company LLC reaffirmed a "buy" rating and issued a $51.00 target price on shares of AtriCure in a research report on Thursday, March 27th. BTIG Research reiterated a "buy" rating on shares of AtriCure in a report on Thursday, March 27th. Finally, JPMorgan Chase & Co. reduced their price objective on AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a research note on Thursday, March 27th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $49.44.

AtriCure Stock Down 0.2 %

NASDAQ ATRC traded down $0.07 on Friday, reaching $32.01. The company had a trading volume of 450,263 shares, compared to its average volume of 655,412. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The company's fifty day moving average is $35.10 and its 200 day moving average is $34.37. AtriCure, Inc. has a 52-week low of $18.94 and a 52-week high of $43.11. The stock has a market capitalization of $1.56 billion, a P/E ratio of -33.69 and a beta of 1.65.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.